Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mifepristone vs GnRHa for Adenomyosis
NCT05151016Phase 1Unknown
- Sponsor
- Women's Hospital, Zhejiang University School of Medicine
- Start
- Dec 2021
- Primary completion
- Dec 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of mifepristone in adenomyosis (2 arms), sponsored by Women's Hospital, Zhejiang University School of Medicine. Primary endpoint: Change from Baseline in Pain on the Visual Analogue Scale at 24 weeks. Status: unknown.
02
Drugs
mifepristone
03
Conditions
adenomyosis
Beyond the preview
Go deeper on NCT05151016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05151016.